Oncology Division
HENPLATIN (Oxaliplatin) HENTAXEL (Docetaxel) TPIAO (Thrombopoietin) ZEFEI (Gemcitabine) ZILONGJIN (Astragalus) HENSETRON (Tropisetron HCl)
Hematology Division
EPOSINO (Epoetin Alfa) FERROFER (Iron Sucrose) TPIAO (Thrombopoietin) WHITE-C (Filgrastim)
Nephrology Division
EPOSINO (Epoetin Alfa) FERROFER (Iron Sucrose)
GoodFellow Pharma Corporation
Generic Name
Recombinant Human Thrombopoietin Injection.

Trade Name
TPIAO

Ingredients
Recombinant human thrombopoietin, Human serum albumin, NaCl

Description
Colorless and transparent liquid without any macroscopic insoluble substance.

Specification
7500U/1ml or 15000 U/1ml

Storage
Store at 2oC-8oC. Avoid direct sunlight.

Package
1 vial, 1ml/vial.

Shelf-life
The shelf life of the drug is three years from the date of manufacture.

TPIAO (Thrombopoietin)

TPIAO 15,000U/mL
(Recombinant Human Thrombopoietin Injection)

Indication
rhTPO is suitable for the thrombocytopenia associated with chemotherapy in cancer patients with solid tumour. rhTPO therapy is recommended to patients with the platelet levels lower than 50109/L or in cases which the doctor find it necessary to increase the patient's platelet level.

Contraindications
  1. Patients with known hypersensitivity to the ingredients of TPO
  2. Patients with severe cerebral and cardiovascular angiopathy
  3. Patients with blood agglutination or a recent history of thrombosis.
  4. Patients shall be incorporated in order to inhibit patients from reusing the rhTPO after infection.

Precautions
  • Blood platelet level may unnecessarily be increased if excessive rhTPO is administered. rhTPO should be under direct medical supervision.
  • While rhTPO treatment is recommended for patients with a blood platelet level lower than 50x109/L, the doctor may find it necessary to increase the concentration of blood platelet in some cases.
  • rhTPO should be administered within 6 to 24 hours after chemotherapy
  • Routine blood examination at a fixed period is suggested and conducted every other day. Attention must be paid to the changes in peripheral blood platelet count. Treatment should be stopped, once blood platelet count has reached normal levels.
Pregnancy and nursing mothers
The safety of TPO therapy in pregnant women has not been established. Because many drugs are excreted in human milk, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.


Manufactured By
Shenyang Sunshine Pharmaceutical Co., Ltd.
No. 3 A1, 10th Road,
Shenyang Economy & Technology
Development Zone, Shenyang 110027, P.R. China

Exclusively Imported By
Goodfellow Pharma Corporation
Unit 3009 Jollibee Plaza Bldg., Emerald Ave.,
Ortigas Center, Pasig City
Tel. Nos.: (632) 632-7031
Fax: (632) 635-3957
E-mail: good_fellow88@yahoo.com
Copyright © 2008 Goodfellow Pharma Corporation
Unit 3009 Jollibee Plaza Bldg.,
Emerald Ave., Ortigas Center 1605 Pasig City

Telephone: (+632) 635-3957 / 632-7031
Mobile No.: (0917) 831-1338

e-mail: good_fellow88@yahoo.com